KLK3 and prostate carcinoma: In the present retrospective study, multivariable models that included known prognostic factors in prostate cancer (e.g., baseline PSA levels, hemoglobin levels, Gleason score, alkaline phosphatase and LDH levels [23], visceral involvement [24] and neutrophil to lymphocyte ratio [25]) revealed that statin use was associated with a 53% reduction in the risk of all-cause mortality, and a 57% reduction in the risk of prostate cancer-specific mortality.